Chemical Structure : Tiragolumab
CAS No.: 1918185-84-8
货号: PC-Ab1006Not For Human Use, Lab Use Only.
The first anti-TIGIT (T-cell immunoglobin and ITIM domain protein) mAb, prevent TIGIT from binding to its ligand, could restore the antitumor response and could complement the activity of anti–PD-L1/PD-1 antibodies. Anti-TIGIT mAb (tiragolumab) has demonstrated promising clinical efficacy in non-small cell lung cancer treatment when combined with an anti-PD-L1 drug (Tecentriq), exhibited remarkable efficacy in PD-L1-positive NSCLC patients in phase II clinical trials..
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥3580 | In stock | |
5 mg | ¥7580 | In stock | |
10 mg | ¥12800 | In stock | |
100 mg | Get quote |
大包装,大折扣!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
The first anti-TIGIT (T-cell immunoglobin and ITIM domain protein) mAb, prevent TIGIT from binding to its ligand, could restore the antitumor response and could complement the activity of anti–PD-L1/PD-1 antibodies. Anti-TIGIT mAb (tiragolumab) has demonstrated promising clinical efficacy in non-small cell lung cancer treatment when combined with an anti-PD-L1 drug (Tecentriq), exhibited remarkable efficacy in PD-L1-positive NSCLC patients in phase II clinical trials.
分子量 | ||
分子式 | Human IgG1-Kappa | |
外观性状 | Solid | |
储存条件 |
|
|
Solubility |
PBS, pH 7.0 Contains no stabilizers or preservatives |
|
Chemical Name/SMILES |
Tiragolumab; MTIG7192A; Anti-human TIGIT; VSTM3; T cell Ig and ITIM domain; T cell immunoreceptor with Ig and ITIM domains; V-set and transmembrane domain-containing protein 3; WUCAM |
1. 1, Yeo J, et al. Pharmaceuticals (Basel). 2021 Feb 28;14(3):200. 2, Houssaini MS, et al. Cancer Treat Res Commun. 2020;25:100239.
备案号:沪ICP备16042516号-1 Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright